Fig. 1. Efficacy of incretin hormones—glycosylated hemoglobin (HbA1c) change from baseline. LR, liraglutide; SM, semaglutide; TZP, tirzepatide. LR 0.6 mg, 1.2 mg, and 1.8 mg (LEAD2 study⁶⁶); LR 3.0 mg (SCALE study¹³); SM 0.5 mg and 1.0 mg (SUSTAIN 1 study⁶⁷); SM 2.4 mg (STEP2 study¹²); TZP 5 mg, 10 mg, and 15 mg (SURPASS 1 study¹⁴).

J Obes Metab Syndr 2022;31:123~133 https://doi.org/10.7570/jomes22001

© JOMES